Zai Lab Limited (ZLAB) ADS Each Repr 10 Ord Shares

Sell:$24.50Buy:$25.50$1.15 (4.44%)

NASDAQ:0.65%
Market closed |
Prices delayed by at least 15 minutes
Sell:$24.50
Buy:$25.50
Change:$1.15 (4.44%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:$24.50
Buy:$25.50
Change:$1.15 (4.44%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.

Key people

Ying Du
Chairman of the Board, Chief Executive Officer, Co-Founder
Joshua L. Smiley
President, Chief Operating Officer
Yajing Chen
Chief Financial Officer
Rafael G. Amado
President, Head of Global Research and Development
Frazor Titus Edmondson
Company Secretary, Chief Legal Officer
John David Diekman
Lead Independent Director
Richard B. Gaynor
Independent Director
William David Lis
Independent Director
Scott William Morrison
Independent Director
Leon Oliver Moulder
Independent Director
Click to see more

Key facts

  • Shares in issue
    1.10bn
  • EPIC
    ZLAB
  • ISIN
    US98887Q1040
  • Location
    China
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $3.02bn
  • Employees
    1,869
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.